
Inhibikase Therapeutics Investor Relations Material
Latest events

Q2 2024
Inhibikase Therapeutics

Q1 2025
14 May, 2025

Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inhibikase Therapeutics Inc
Access all reports
Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.
Latest articles
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
Ticker symbol
IKT
Country
🇺🇸 United States